SCHEMBL26260609

SCHEMBL26260609

Nc1cc(SCc2nc3cc(Nc4ccccc4)ccc3[nH]2)nc(C(F)(F)F)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCB1 P08183 9/20 0.40
▸ CDK2 P24941 1/20 0.39
▸ NPC1 O15118 3/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ LMNA P02545 2/20 0.38
▸ PARP14 Q460N5 2/20 0.36
▸ ERBB2 P04626 1/20 0.36
▸ NTRK1 P04629 1/20 0.35
▸ NTRK2 Q16620 1/20 0.35
▸ MAPT P10636 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26260528 0.92 ABCB1 (0.42) ABCB1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL21611990 0.82 GRIN1 (0.43) ABCB1NPC1RAB9ACYP1A2CYP3A4
SCHEMBL26260607 0.82 NPC1 (0.43) ABCB1NPC1RAB9ACYP1A2CYP3A4
SCHEMBL30041556 0.82 NPC1 (0.43) ABCB1NPC1RAB9ACYP1A2CYP3A4
SCHEMBL21612011 0.81 NPC1 (0.42) ABCB1NPC1RAB9ACYP1A2CYP3A4
SCHEMBL21612006 0.77 GAA (0.44) NPC1RAB9ASMN1; SMN2LMNAMEN1
SCHEMBL21614659 0.77 GRIN1 (0.34) ABCB1NPC1RAB9ACYP1A2CYP3A4
SCHEMBL21611965 0.76 GRIN1 (0.35) ABCB1NPC1RAB9ACYP1A2CYP3A4
SCHEMBL21614675 0.76 CYP1A2 (0.42) ABCB1NPC1RAB9ACYP1A2CYP3A4
SCHEMBL23618336 0.75 NPC1 (0.44) ABCB1NPC1RAB9ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4085054-B1 NEW PQSR INVERSE AGONISTS HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) 2025-02-19 — — EP disclosed
US-20230286942-A1 NEW PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2023-09-14 — — US disclosed
EP-4085054-A1 NEW PQSR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2022-11-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286942-A1 NEW PqsR INVERSE AGONISTS QRFPR, P2RY11, GPR55 ABCB1 1506/4885CDK2 2737/4885NPC1 4374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback